Search

Displaying results 4271 - 4280 of 7059 in total
  1. Drug

    Nadofaragene firadenovec

    go.drugbank.com/drugs/DB17381
    ApprovedInvestigational

    Nadofaragene firadenovec (nadofaragene firadenovec-vncg) is a recombinant non-replicating adenovirus serotype 5 vector containing a transgene encoding human interferon alfa-2b (IFNα2b). … It is the first gene therapy approved by the FDA for the treatment of bladder cancer.[L44381,L44431] BCG-unresponsive NMIBC has a high recurrence and is notably difficult to treat.

  2. Drug

    TRGFT-201

    go.drugbank.com/drugs/DB23064
    ApprovedInvestigational

    [L64070,L64071] Orca-T was approved by the FDA on June 30, 2026 for use in matched-donor hematopoietic stem cell transplantation with a myeloablative preparative regimen, for hematopoietic and immunologic … [L64070,L64071] It is the first regulatory T cell (Treg)-based immunotherapy approved by the FDA.[L64071]

  3. Drug

    Scorpion (centruroides) immune Fab2 antivenin (equine)

    go.drugbank.com/drugs/DB13905
    Approved

    This drug is a polyvalent antivenin proven to be useful against scorpion stings. … Envenomation by a scorpion sting can result in serious cardiovascular effects [A32483].

  4. Drug

    Cresol

    go.drugbank.com/drugs/DB11143
    Approved

    Cresol is a hydroxytoluene that can be extracted naturally from coal tar or made synthetically. Pure cresol is a mixture of ortho-, meta-, and para- isomers. … At concentrations normally found in the environment however, cresols do not pose any significant risk for the general population.

  5. Drug

    Chlormadinone acetate

    go.drugbank.com/drugs/DB15903
    ApprovedWithdrawn

    Chlormadinone acetate is a progesterone derivative first synthesized in 1961. … In 1972, the FDA withdrew its approval for the use of chlormadinone acetate in all products.

  6. Drug

    Resmetirom

    go.drugbank.com/drugs/DB12914
    ApprovedInvestigational

    Resmetirom is a thyroid hormone receptor-beta (THR-beta) agonist. … On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD

  7. Drug

    Depemokimab

    go.drugbank.com/drugs/DB18846
    ApprovedInvestigational

    Depemokimab is a humanized Immunoglobulin G1 (IgG1) monoclonal antibody and a long-acting drug. … [A275338] Depemokimab blocks interleukin-5 (IL-5), a key cytokine that regulates eosinophil maturation, survival, and recruitment.

  8. Drug

    Tadalafil

    go.drugbank.com/drugs/DB00820
    ApprovedInvestigational

    In contrast to other PDE5 inhibitors like [sildenafil], tadalafil has greater selectivity for PDE5 and a longer half-life which has made it a more suitable option for chronic once-daily dosing in the treatment … [L39100, L39105] It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH.

    Products: N/a, TADAL 1A PHARMA PAH 20MG
  9. Drug

    Lapatinib

    go.drugbank.com/drugs/DB01259
    ApprovedInvestigational

    Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. … It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine.

  10. Drug

    Zongertinib

    go.drugbank.com/drugs/DB18762
    ApprovedInvestigational

    Zongertinib is a selective, irreversible tyrosine kinase inhibitor that targets human epidermal growth factor receptor 2 (HER2). … [L53873,A274363] On August 8, 2025, the US FDA granted accelerated approval to zongertinib for the treatment of advanced forms of non-small cell lung cancer (NSCLC) with HER2 tyrosine kinase domain